Drug intelligence / Profile preview

NNC9204-0530 + liraglutide

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC9204-0530 + liraglutide is a combination of two drugs under investigation for obesity treatment. *NNC9204-0530* is a synthetic peptide and a glucagon analogue developed by Novo Nordisk, acting as a **glucagon receptor agonist** to increase energy expenditure and promote weight loss[4][7]. *Liraglutide* is a GLP-1 (glucagon-like peptide-1) receptor agonist, also by Novo Nordisk, which enhances insulin secretion, suppresses glucagon secretion, delays gastric emptying, and reduces appetite[10]. The combination aims to harness possible additive or synergistic effects for more effective obesity management compared to monotherapy with liraglutide[1][2][5].

Other names: NN 9030 + liraglutide

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on NNC9204-0530 + liraglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC9204-0530 + liraglutide.

Explore the full profile